Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is rare with a poor outcome and is resistant to conventional cytotoxic chemotherapy. The efficacy and safety of durvalumab and tremelimumab for treating recurrent or metastatic PSCs were assessed by a nonrandomized, open‐label, phase II study. METHOD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorac Cancer
Hauptverfasser: Kim, Miso, Keam, Bhumsuk, Ock, Chan‐Young, Kim, Se Hyun, Kim, Yu Jung, Lim, Sun Min, Kim, Jin‐Soo, Kim, Tae Min, Hong, Sook‐Hee, Ahn, Mi Sun, Shin, Seong Hoon, Kang, Eun Joo, Kim, Dong‐Wan, Im, Sun‐Wha, Kim, Jong‐Il, Lee, Jong Seok, Kim, Joo‐Hang, Heo, Dae Seog
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons Australia, Ltd 2020
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7705626/
https://ncbi.nlm.nih.gov/pubmed/33026712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13684
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge